ADULT AIDS CLINICAL TRIALS UNIT

成人艾滋病临床试验单位

• 批准号: 2003802
• 负责人: Michael S. Saag
• 金额: $ 165.76万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-04-01 至 1999-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2003802
• 关键词: AIDS; AIDS therapy; HIV infections; antiAIDS agent; clinical research; cooperative study; human immunodeficiency virus 1; human subject; human therapy evaluation; pathologic process

This is a competitive renewal of the Birmingham ACTU, established in 1992 at the UAB AIDS Outpatient (1917) Clinic, and is submitted in conjunction with the ACTG Group application led by Robert T. Schooley, MD (PI). The Birmingham ACTU has been a national leader in the development and implementation of clinical trials that link therapeutics and pathogenesis, a high priority of the ACTG recompetition. Investigators from UAB have assumed leadership positions within the ACTG and have played a pivotal role in the establishment and performance of the Group's Scientific Agenda. This application builds on the experience of the Birmingham ACTU and adds investigators from Emory University as important new contributors to the ACTG effort through the establishment of a subunit at the Ponce de Leon Clinic in Atlanta. The primary focus of the UAB/Emory ACTU is to: (i) Establish collaborative studies within the ACTG which focus on the clinical significance and therapeutic implications of recent insights into HIV pathogenesis elucidated at our site; (ii) Further development improved therapeutic approaches in the treatment of cytomegalovirus, mycobacterial, human papilloma virus, herpes-related viruses, mycoplasma, and cryptococcal disease, areas where UAB/Emory investigators have made critical contributions and have unique expertise; (iii) Improve access of women and minorities to ACTG-related clinical trials through the 1917 Women's Clinic and the Women's Clinic at the Ponce de Leon Center and through targeted outreach programs to HIV-infected African Americans, the most rapidly growing population of HIV-infected patients, especially in the Southeastern United States; and (iv) Contribute to the overall mission and Scientific Agenda of the ACTG through active participation in Group activities and provision of leadership within key administrative committees. Our current level of performance, scientific contributions, history of leadership within the Group, geographic location within the most rapidly growing population of newly acquired HIV disease (Southeastern United States), and our unique expertise in critical areas of the Group's scientific focus makes the UAB/Emory ACTU an ideal site for the conduct of clinical trials through the ACTG network.

这是伯明翰Actu的竞争性更新 1992年，在UAB AIDS门诊（1917）诊所，并提交 与罗伯特·T（Robert T）领导的ACTG小组申请一起。 医学博士学位（PI）。 伯明翰Actu一直是国家领导人 在临床试验的开发和实施中 治疗和发病机理，ACTG的高度优先级 重新计算。 来自UAB的调查人员已担任领导 在ACTG中的职位，并在 该小组科学议程的建立和表现。 该应用程序建立在伯明翰Actu的经验基础上 并将埃默里大学的调查人员添加为重要的新 通过建立A ACTG努力的贡献者 亚特兰大Ponce de Leon诊所的亚基。 UAB/Emory Actu的主要重点是： （i）在ACTG中建立协作研究，重点是 最近的临床意义和治疗意义 在我们的部位阐明了对HIV发病机理的见解； （ii）进一步发展改善了治疗方法 巨细胞病毒，分枝杆菌，人乳头瘤病毒的治疗， 与疱疹有关的病毒，支原体和隐球菌疾病，地区 UAB/Emory调查人员做出了关键贡献和 拥有独特的专业知识； （iii）改善妇女和少数群体与ACTG相关的机会 通过1917年妇女诊所和妇女的临床试验 Ponce de Leon中心的诊所，并通过有针对性的外展 对艾滋病毒感染的非裔美国人的计划，最迅速的计划 艾滋病毒感染患者的人群不断增长，尤其是 美国东南部；和 （iv）为整体使命和科学议程做出了贡献 通过积极参与小组活动和规定的行动 主要行政委员会内的领导力。 我们目前的绩效水平，科学贡献，历史 小组内的领导力，地理位置最多 新近获得的艾滋病毒疾病的迅速增长 （美国东南部），以及我们在关键方面的独特专业知识 该小组科学重点的领域使UAB/Emory Actu成为 通过ACTG进行临床试验的理想场所 网络。